1 unchanged sentence
Insider Trading Arrangements
−Removed: During the quarter ended June 30, 2024, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K.
+Added: During the quarter ended September 30, 2024, none of our directors or officers (as defined in Section 16 of the Securities Exchange Act of 1934, as amended) adopted or terminated any contract, instruction or written plan for the purchase or sale of our securities that was intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) or any “non-Rule 10b5-1 trading arrangement,” as defined in Item 408(a) of Regulation S-K.
(a) Exhibits.
1 unchanged sentence
Form Incorporated By Reference File No.
−Removed: Agreement and Plan of Merger, dated January 22, 2024, by and among Inhibrx, Inc., Aventis, Inc.
−Removed: and Art Acquisition Sub, Inc.
−Removed: 8-K 001-39452 1/23/2024
−Removed: Separation and Distribution Agreement, dated January 22, 2024, by and among Inhibrx, Inc., Ibex SpinCo, Inc.
−Removed: and Aventis Inc.
−Removed: 8-K 001-39452 1/23/2024
+Added: Agreement and Plan of Merger, dated as of January 22, 2024, by and among Inhibrx, Inc., Aventis Inc., and Art Acquisition Sub, Inc.
+Added: Separation and Distribution Agreement, dated as of January 22, 2024, by and among Inhibrx, Inc., Ibex SpinCo, Inc., and Aventis Inc.
Amended & Restated Certificate of Incorporation of Inhibrx Biosciences, Inc.
−Removed: 8-K 001-42031 5/30/2024
Amended & Restated Bylaws of Inhibrx Biosciences, Inc.
−Removed: 8-K 001-42031 5/30/2024
−Removed: 4.1 Form of Warrant to Purchase Stock.
−Removed: 10 001-42031 4/25/2024
−Removed: Transition Services Agreement, dated as of May 29, 2024, by and between Inhibrx Biosciences, Inc.
−Removed: and Inhibrx, Inc.
−Removed: 8-K 001-42031 5/30/2024
−Removed: 10.2 Form of Indemnification Agreement.
−Removed: 10 001-42031 4/25/2024
−Removed: Registration Rights Agreement, dated as of May 29, 2024, by and among Inhibrx Biosciences, Inc.
−Removed: and the parties thereto.
−Removed: 8-K 001-42031 5/30/2024
−Removed: 10.4+ Executive Employment Agreement, effective as of May 30, 2024, by and between Inhibrx Biosciences, Inc.
−Removed: and Mark Lappe.
−Removed: S-1 333-280127 6/11/2024
−Removed: 10.5+ Executive Employment Agreement, effective as of May 30, 2024, by and between Inhibrx Biosciences, Inc.
−Removed: and Brendan Eckelman, Ph.D.
−Removed: S-1 333-280127 6/11/2024
−Removed: 10.6+ Executive Employment Agreement, effective as of May 30, 2024, by and between Inhibrx Biosciences, Inc.
−Removed: and Kelly Deck.
−Removed: S-1 333-280127 6/11/2024
−Removed: 10.7+ 2024 Omnibus Incentive Plan.
−Removed: S-8 333-279840 5/30/2024
−Removed: 10.8+ Form of Stock Option Grant Notice under the 2024 Omnibus Incentive Plan.
−Removed: 8-K 001-42031 5/30/2024
−Removed: 10.9+ Form of Restricted Stock Unit Agreement under the 2024 Omnibus Incentive Plan.
−Removed: S-8 333-279840 5/30/2024
−Removed: License Agreement, dated December 20, 2018, by and between Inhibrx, Inc.
−Removed: and bluebird bio, Inc.
−Removed: S-1 333-231907 6/3/2019
−Removed: Option and License Agreement, dated June 9, 2020, by and between Inhibrx, Inc.
−Removed: and bluebird bio, Inc.
−Removed: S-1 333-240135 7/28/2020
−Removed: License Agreement, dated July 1, 2013, by and between INBRX 103, LLC and Celgene Corporation.
−Removed: S-1 333-231907 6/3/2019
−Removed: Amendment to License Agreement, dated November 23, 2018, by and among Inhibrx, Inc.
−Removed: , INBRX 103, LLC and Celgene Corporation.
−Removed: S-1 333-231907 6/3/2019
−Removed: Nonemployee Director Compensation Policy.
+Added: F orm of Warrant to Purchase Stock
31.1 Certification of Principal Executive Officer pursuant to Rule 13a-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
12 unchanged sentences
Pursuant to Item 601(a)(6) of Regulation S-K, certain information from this exhibit have been redacted as their disclosure would constitute a clearly unwarranted invasion of personal privacy.
−Removed: † Pursuant to Item 601(b)(10) of Regulation S-K, certain confidential portions of this exhibit have been omitted by means of marking such portions with asterisks as the identified confidential portions (i) are not material and (ii) would be competitively harmful if publicly disclosed.
−Removed: * This certification is deemed not filed for purpose of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
−Removed: + Management compensation plan or arrangement.
+Added: * This certification is deemed not filed for purposes of section 18 of the Exchange Act or otherwise subject to the liability of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act or the Exchange Act.
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
INHIBRX BIOSCIENCES, INC.
−Removed: August 13, 2024
+Added: November 14, 2024
Chief Executive Officer and Chairman
(Principal Executive Officer)
−Removed: August 13, 2024
+Added: November 14, 2024
Chief Financial Officer
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.